10,065 Shares in Fulgent Genetics, Inc. (NASDAQ:FLGT) Acquired by Wealthspire Advisors LLC

Wealthspire Advisors LLC bought a new stake in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 10,065 shares of the company’s stock, valued at approximately $186,000.

Several other hedge funds also recently bought and sold shares of the stock. State Street Corp lifted its position in shares of Fulgent Genetics by 1.4% in the third quarter. State Street Corp now owns 793,545 shares of the company’s stock valued at $17,244,000 after acquiring an additional 10,868 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Fulgent Genetics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 502,869 shares of the company’s stock valued at $10,930,000 after purchasing an additional 13,320 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Fulgent Genetics by 113.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 338,044 shares of the company’s stock worth $7,346,000 after purchasing an additional 179,477 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Fulgent Genetics during the 3rd quarter worth about $5,854,000. Finally, Invenomic Capital Management LP grew its holdings in shares of Fulgent Genetics by 98.9% during the third quarter. Invenomic Capital Management LP now owns 249,747 shares of the company’s stock worth $5,427,000 after buying an additional 124,185 shares in the last quarter. Hedge funds and other institutional investors own 48.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on FLGT shares. Piper Sandler lowered their target price on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating for the company in a research note on Monday, November 11th. StockNews.com cut Fulgent Genetics from a “hold” rating to a “sell” rating in a report on Wednesday, November 27th.

Fulgent Genetics Stock Down 3.4 %

Shares of NASDAQ FLGT opened at $15.69 on Friday. The stock has a market capitalization of $479.91 million, a PE ratio of -2.84 and a beta of 1.39. The firm has a fifty day moving average of $17.37 and a 200-day moving average of $19.55. Fulgent Genetics, Inc. has a 52-week low of $15.69 and a 52-week high of $25.11.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.